We are live on !
Find out more
NEA Management Company Portfolio holdings
AUM
$1.59B
Turnover
7.41%
1-Year Est. Return
234.06%
This Fund
S&P 500
This Quarter Est. Return
+26.7%
1 Year Est. Return
+234.06%
3 Year Est. Return
+822.97%
5 Year Est. Return
+865.41%
10 Year Est. Return
+12,585.11%
AUM
$1.59B
AUM Growth
-$171M
(-9.7%)
Cap. Flow
-$411M
Cap. Flow % of AUM
Cap. Flow %
-25.91%
Top 10 Holdings %
Top 10 Hldgs %
89.82%
Holding
27
New
1
Increased
–
Reduced
2
Closed
1
Avg Time Held
4.6
years
Top 10 Avg Time Held
1.2
years
Top 20 Avg Time Held
2.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Karyopharm Therapeutics
KPTI
|
+$5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arcellx
ACLX
|
+$350M |
| 2 |
Celcuity
CELC
|
+$66.3M |
| 3 |
CVRx
CVRX
|
+$462K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.43% |
| 2 | Consumer Staples | 4.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Trevi Therapeutics
TRVI
$1.69B
| $247M | 15.53% |
13,222,228
| – | – |
2019 Q2
28 quarters
|
|
2
MBX Biosciences
MBX
$2.5B
| $200M | 12.56% |
3,614,486
| – | – |
2024 Q3
7 quarters
|
|
3
Monte Rosa Therapeutics
GLUE
$852M
| $186M | 11.72% |
7,692,298
| – | – |
2021 Q2
20 quarters
|
|
|
4
Celcuity
CELC
$2.84B
| $179M | 11.27% |
1,710,561
-575,000
| -25% | -$66.3M |
2022 Q4
14 quarters
|
|
5
SpyGlass Pharma
SGP
$831M
| $165M | 10.36% |
7,392,301
| – | – |
2026 Q1
1 quarter
|
|
6
Savara
SVRA
$939M
| $151M | 9.49% |
24,471,264
| – | – |
2021 Q1
21 quarters
|
|
7
Zenas BioPharma
ZBIO
$1.75B
| $102M | 6.43% |
4,023,219
| – | – |
2024 Q3
7 quarters
|
|
8
Coursera
COUR
$1.31B
| $72.6M | 4.57% |
12,867,769
| – | – |
2021 Q1
21 quarters
|
|
9
Aurinia Pharmaceuticals
AUPH
$2.2B
| $67.4M | 4.24% |
3,969,834
| – | – |
2014 Q3
47 quarters
|
|
10
CRISPR Therapeutics
CRSP
$4.81B
| $57.7M | 3.64% |
1,058,570
| – | – |
2016 Q4
38 quarters
|
|
11
Oric Pharmaceuticals
ORIC
$1.29B
| $44.6M | 2.81% |
4,118,621
| – | – |
2024 Q1
9 quarters
|
|
12
Phathom Pharmaceuticals
PHAT
$550M
| $21.3M | 1.34% |
1,960,169
| – | – |
2023 Q2
12 quarters
|
|
13
Korro Bio
KRRO
$126M
| $17.1M | 1.08% |
1,297,893
| – | – |
2023 Q4
10 quarters
|
|
14
X4 Pharmaceuticals
XFOR
$263M
| $15.1M | 0.95% |
3,233,743
| – | – |
2022 Q3
15 quarters
|
|
15
Champions Oncology
CSBR
$65M
| $10.6M | 0.66% |
1,713,720
| – | – |
2015 Q3
43 quarters
|
|
16
Nkarta
NKTX
$128M
| $10.1M | 0.64% |
3,568,781
| – | – |
2020 Q3
23 quarters
|
|
|
17
CVRx
CVRX
$34.1M
| $10M | 0.63% |
1,954,440
-71,643
| -4% | -$462K |
2021 Q2
20 quarters
|
|
18
Black Diamond Therapeutics
BDTX
$101M
| $8.23M | 0.52% |
4,448,757
| – | – |
2020 Q1
25 quarters
|
|
|
19
Karyopharm Therapeutics
KPTI
$8.05M
| $5.64M | 0.35% |
+576,780
| New | +$5M |
2026 Q2
0 quarters
|
|
20
Inventiva
IVA
$711M
| $5.53M | 0.35% |
1,462,586
| – | – |
2020 Q3
23 quarters
|
|
21
LeonaBio Inc
LONA
$48.8M
| $4.27M | 0.27% |
464,398
| – | – |
2025 Q4
2 quarters
|
|
22
Senti Biosciences Holdings
SNTI
$6.95M
| $4.15M | 0.26% |
3,775,615
| – | – |
2022 Q2
16 quarters
|
|
23
Marker Therapeutics
MRKR
$18M
| $2.39M | 0.15% |
1,625,678
| – | – |
2018 Q4
30 quarters
|
|
24
OnKure Therapeutics
OKUR
$83.4M
| $2.18M | 0.14% |
478,548
| – | – |
2021 Q2
20 quarters
|
|
25
ImageneBio Inc
IMA
$45.4M
| $295K | 0.02% |
50,005
| – | – |
2023 Q3
11 quarters
|
|
Similar funds
ACM
NEA Management Company's Q2 2026 Portfolio in Review
As of Q2 2026, NEA Management Company held 27 positions worth $1.59B, down 9.7% from $1.76B the previous quarter. Its ten largest holdings account for 90% of the portfolio.
NEA Management Company withdrew a net $411M in Q2 2026, closing 1 position and reducing 2 holdings. Its most notable exit was Arcellx, an estimated $350M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Consumer Staples.
Against the trend, NEA Management Company opened a new position in Karyopharm Therapeutics worth $5.64M.
- NEA Management Company's largest Q2 2026 buy was Karyopharm Therapeutics: 576,780 shares worth $5.64M.
- NEA Management Company's biggest Q2 2026 reduction was Celcuity, cutting an estimated $66.3M.
- NEA Management Company fully exited Arcellx in Q2 2026, selling an estimated $350M.
- NEA Management Company's ten largest holdings make up 90% of its $1.59B portfolio in Q2 2026.
- NEA Management Company opened 1 new position and closed 1 in Q2 2026.
- NEA Management Company's portfolio value fell 9.7% quarter-over-quarter to $1.59B.
Based on NEA Management Company's 13F filing for Q2 2026, filed 14 Aug 2026.